{"transactions":[{"id":717587,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-07-02T21:16:41.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":221100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\") granted on June 30, 2026 pursuant to an incentive award letter agreement. The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment by the Issuer without cause or by the reporting person for good reason, subject to the reporting person's continued employment with the Issuer on the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":841640,"source":{"system":"sec-edgar","filing":"0001628280-26-047034","document":"wk-form4_1783026998.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235635/000162828026047034/wk-form4_1783026998.xml","form_type":"4"}},{"id":896212,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-02-18T22:43:12.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":33294,"price":3.99,"value":132843.06,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":620540,"source":{"system":"sec-edgar","filing":"0001628280-26-009280","document":"wk-form4_1771454589.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235635/000162828026009280/wk-form4_1771454589.xml","form_type":"4"}},{"id":896211,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-02-18T22:43:12.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":294800,"price":3.99,"value":1176252.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2026, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event."}],"balance_after":653834,"source":{"system":"sec-edgar","filing":"0001628280-26-009280","document":"wk-form4_1771454589.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235635/000162828026009280/wk-form4_1771454589.xml","form_type":"4"}},{"id":975787,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2025-12-09T22:09:31.000Z","date":"2025-12-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":49508,"price":3.29,"value":162881.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":359034,"source":{"system":"sec-edgar","filing":"0001628280-25-056169","document":"wk-form4_1765318168.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235635/000162828025056169/wk-form4_1765318168.xml","form_type":"4"}},{"id":1266942,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2025-02-14T23:23:22.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":220000,"price":1.61,"value":354200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2025, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event."}],"balance_after":408542,"source":{"system":"sec-edgar","filing":"0001628280-25-005863","document":"wk-form4_1739575395.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235635/000162828025005863/wk-form4_1739575395.xml","form_type":"4"}},{"id":1338817,"issuer":{"id":6502,"kind":"organization","name":"ADC Therapeutics SA"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2024-12-10T01:35:22.000Z","date":"2024-12-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":41458,"price":3.13,"value":129763.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted."}],"balance_after":188542,"source":{"system":"sec-edgar","filing":"0001628280-24-050540","document":"wk-form4_1733794514.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235635/000162828024050540/wk-form4_1733794514.xml","form_type":"4"}},{"id":2255792,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:25:30.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":163963,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":4.42,"underlying":"Common Stock","underlying_shares":163963},"source":{"system":"sec-edgar","filing":"0000899243-22-019789","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019789/doc4.xml","form_type":"4"}},{"id":2255791,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:25:30.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":254165,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":2.73,"underlying":"Common Stock","underlying_shares":254165},"source":{"system":"sec-edgar","filing":"0000899243-22-019789","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019789/doc4.xml","form_type":"4"}},{"id":2255790,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:25:30.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":170227,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":2.92,"underlying":"Common Stock","underlying_shares":170227},"source":{"system":"sec-edgar","filing":"0000899243-22-019789","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019789/doc4.xml","form_type":"4"}},{"id":2255789,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:25:30.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":177453,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":2.7,"underlying":"Common Stock","underlying_shares":177453},"source":{"system":"sec-edgar","filing":"0000899243-22-019789","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019789/doc4.xml","form_type":"4"}},{"id":2255788,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:25:30.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":217725,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":2.66,"underlying":"Common Stock","underlying_shares":217725},"source":{"system":"sec-edgar","filing":"0000899243-22-019789","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019789/doc4.xml","form_type":"4"}},{"id":2255787,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:25:30.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":212900,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":1.12,"underlying":"Common Stock","underlying_shares":212900},"source":{"system":"sec-edgar","filing":"0000899243-22-019789","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019789/doc4.xml","form_type":"4"}},{"id":2255786,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:25:30.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":2.29,"underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0000899243-22-019789","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019789/doc4.xml","form_type":"4"}},{"id":2255785,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-05-26T17:25:30.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":124234,"price":5.6,"value":695710.4,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each Company performance restricted stock unit (\"Company PSU\") means any performance stock unit granted under the Company Equity Plan. At the Effective Time, each Company PSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company PSU (at the target level of performance) immediately prior to the Effective Time multiplied by (ii) the Merger Consideration."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the \"Company\"),  Halozyme Therapeutics, Inc., a Delaware corporation (\"Parent\"), and Atlas Merger Sub, Inc., a Delaware corporation (\"Purchaser\") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of May 24, 2022 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the \"Merger Consideration\") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-019789","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019789/doc4.xml","form_type":"4"}},{"id":2255784,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-05-26T17:25:30.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":202139,"price":5.6,"value":1131978.4,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Each Company restricted stock unit (\"Company RSU\") means any restricted stock unit granted under the Company Equity Plan. At the Effective Time, each Company RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the \"Company\"),  Halozyme Therapeutics, Inc., a Delaware corporation (\"Parent\"), and Atlas Merger Sub, Inc., a Delaware corporation (\"Purchaser\") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of May 24, 2022 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the \"Merger Consideration\") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-019789","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019789/doc4.xml","form_type":"4"}},{"id":2255783,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-05-26T17:25:30.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":414470,"price":5.6,"value":2321032.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the \"Company\"),  Halozyme Therapeutics, Inc., a Delaware corporation (\"Parent\"), and Atlas Merger Sub, Inc., a Delaware corporation (\"Purchaser\") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of May 24, 2022 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the \"Merger Consideration\") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-019789","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019789/doc4.xml","form_type":"4"}},{"id":2351257,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2022-03-04T18:34:54.000Z","date":"2022-03-03","kind":"tax_withholding","acquired":false,"shares":13635,"price":3.8,"value":51813.0,"ownership":{"direct":true},"balance_after":616609,"source":{"system":"sec-edgar","filing":"0001016169-22-000031","document":"wf-form4_164643687992101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000101616922000031/wf-form4_164643687992101.xml","form_type":"4"}},{"id":2351256,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2022-03-04T18:34:54.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":26044,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 13, 2019, Mr. Graham was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2021. The number of shares acquired represent the total number of shares earned upon achievement of one of the performance goals, which was certified and vested on March 3, 2022. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liabilities in connection with the vesting of the performance stock unit award and were not actually sold."}],"balance_after":630244,"source":{"system":"sec-edgar","filing":"0001016169-22-000031","document":"wf-form4_164643687992101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000101616922000031/wf-form4_164643687992101.xml","form_type":"4"}},{"id":2386290,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2022-02-18T19:19:06.000Z","date":"2022-02-16","kind":"tax_withholding","acquired":false,"shares":13299,"price":3.66,"value":48674.34,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 13, 2019, Mr. Graham was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2021. The number of shares acquired represent the total number of shares earned upon achievement of one of the performance goals, which was certified and vested on February 16, 2022. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liabilities in connection with the vesting of the performance stock unit award and were not actually sold."}],"balance_after":604200,"source":{"system":"sec-edgar","filing":"0001016169-22-000016","document":"wf-form4_164522993007298.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000101616922000016/wf-form4_164522993007298.xml","form_type":"4"}},{"id":2386289,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2022-02-18T19:19:06.000Z","date":"2022-02-16","kind":"grant","acquired":true,"shares":23068,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 13, 2019, Mr. Graham was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2021. The number of shares acquired represent the total number of shares earned upon achievement of one of the performance goals, which was certified and vested on February 16, 2022. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liabilities in connection with the vesting of the performance stock unit award and were not actually sold."}],"balance_after":617499,"source":{"system":"sec-edgar","filing":"0001016169-22-000016","document":"wf-form4_164522993007298.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000101616922000016/wf-form4_164522993007298.xml","form_type":"4"}},{"id":2670746,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2021-06-14T18:21:44.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":163963,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest and become exercisable in three equal annual installments on the first, second and third anniversaries of the grant date."}],"balance_after":163963,"derivative":{"exercise_price":4.42,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":163963},"source":{"system":"sec-edgar","filing":"0001209191-21-040328","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121040328/doc4.xml","form_type":"4"}},{"id":2670745,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2021-06-14T18:21:44.000Z","date":"2021-06-13","kind":"tax_withholding","acquired":false,"shares":14790,"price":4.45,"value":65815.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."}],"balance_after":594431,"source":{"system":"sec-edgar","filing":"0001209191-21-040328","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121040328/doc4.xml","form_type":"4"}},{"id":2670744,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2021-06-14T18:21:44.000Z","date":"2021-06-11","kind":"tax_withholding","acquired":false,"shares":23010,"price":4.45,"value":102394.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."}],"balance_after":609221,"source":{"system":"sec-edgar","filing":"0001209191-21-040328","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121040328/doc4.xml","form_type":"4"}},{"id":2670743,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2021-06-14T18:21:44.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":85973,"price":4.42,"value":380000.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant."}],"balance_after":632231,"source":{"system":"sec-edgar","filing":"0001209191-21-040328","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121040328/doc4.xml","form_type":"4"}},{"id":2674488,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2021-06-10T17:38:34.000Z","date":"2021-06-08","kind":"tax_withholding","acquired":false,"shares":15996,"price":4.39,"value":70222.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."}],"balance_after":546258,"source":{"system":"sec-edgar","filing":"0001209191-21-039591","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121039591/doc4.xml","form_type":"4"}},{"id":2815892,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2021-03-03T18:32:39.000Z","date":"2021-03-01","kind":"tax_withholding","acquired":false,"shares":23992,"price":4.5,"value":107964.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 8, 2018, Mr. Graham was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2020. The number of shares acquired represent the number of shares earned upon achievement of one of the performance goals, which was certified and vested on March 1, 2021. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liability in connection with the vesting of the performance stock unit award and were not actually sold."}],"balance_after":562254,"source":{"system":"sec-edgar","filing":"0001209191-21-017266","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121017266/doc4.xml","form_type":"4"}},{"id":2815891,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2021-03-03T18:32:39.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":45829,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 8, 2018, Mr. Graham was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2020. The number of shares acquired represent the number of shares earned upon achievement of one of the performance goals, which was certified and vested on March 1, 2021. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liability in connection with the vesting of the performance stock unit award and were not actually sold."}],"balance_after":586246,"source":{"system":"sec-edgar","filing":"0001209191-21-017266","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121017266/doc4.xml","form_type":"4"}},{"id":2847104,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-19T19:07:22.000Z","date":"2021-02-18","kind":"exercise","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested and became exercisable in equal quarterly installments over the three-year period following the grant date of June 2, 2016."}],"balance_after":0,"derivative":{"exercise_price":1.12,"expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-21-012543","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121012543/doc4.xml","form_type":"4"}},{"id":2847103,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2021-02-19T19:07:22.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":5000,"price":5.05,"value":25250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":540417,"source":{"system":"sec-edgar","filing":"0001209191-21-012543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121012543/doc4.xml","form_type":"4"}},{"id":2847102,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2021-02-19T19:07:22.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":40000,"price":4.91,"value":196400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":545417,"source":{"system":"sec-edgar","filing":"0001209191-21-012543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121012543/doc4.xml","form_type":"4"}},{"id":2847101,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2021-02-19T19:07:22.000Z","date":"2021-02-18","kind":"exercise","acquired":true,"shares":45000,"price":1.12,"value":50400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":585417,"source":{"system":"sec-edgar","filing":"0001209191-21-012543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121012543/doc4.xml","form_type":"4"}},{"id":2847100,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2021-02-19T19:07:22.000Z","date":"2021-02-17","kind":"tax_withholding","acquired":false,"shares":42073,"price":4.73,"value":199005.29,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 8, 2018, Mr. Graham was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2020. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, which was certified and vested on February 17, 2021. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liability in connection with the vesting of the performance stock unit award and were not actually sold."}],"balance_after":540417,"source":{"system":"sec-edgar","filing":"0001209191-21-012543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121012543/doc4.xml","form_type":"4"}},{"id":2847099,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2021-02-19T19:07:22.000Z","date":"2021-02-17","kind":"grant","acquired":true,"shares":80365,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 8, 2018, Mr. Graham was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2020. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, which was certified and vested on February 17, 2021. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liability in connection with the vesting of the performance stock unit award and were not actually sold."}],"balance_after":582490,"source":{"system":"sec-edgar","filing":"0001209191-21-012543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121012543/doc4.xml","form_type":"4"}},{"id":3110947,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2020-06-15T19:09:41.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":254165,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest and become exercisable in three equal annual installments on the first, second and third anniversaries of the grant date."}],"balance_after":254165,"derivative":{"exercise_price":2.73,"expiration_date":"2030-06-11","underlying":"Common Stock","underlying_shares":254165},"source":{"system":"sec-edgar","filing":"0001209191-20-036778","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919120036778/doc4.xml","form_type":"4"}},{"id":3110946,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2020-06-15T19:09:41.000Z","date":"2020-06-13","kind":"tax_withholding","acquired":false,"shares":15036,"price":2.78,"value":41800.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."}],"balance_after":502125,"source":{"system":"sec-edgar","filing":"0001209191-20-036778","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919120036778/doc4.xml","form_type":"4"}},{"id":3110945,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2020-06-15T19:09:41.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":131868,"price":2.73,"value":359999.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant."}],"balance_after":517161,"source":{"system":"sec-edgar","filing":"0001209191-20-036778","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919120036778/doc4.xml","form_type":"4"}},{"id":3117305,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2020-06-09T18:30:21.000Z","date":"2020-06-08","kind":"tax_withholding","acquired":false,"shares":16261,"price":3.13,"value":50896.93,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."}],"balance_after":385293,"source":{"system":"sec-edgar","filing":"0001209191-20-035382","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919120035382/doc4.xml","form_type":"4"}},{"id":3117304,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2020-06-09T18:30:21.000Z","date":"2020-06-07","kind":"tax_withholding","acquired":false,"shares":17994,"price":3.12,"value":56141.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."}],"balance_after":401554,"source":{"system":"sec-edgar","filing":"0001209191-20-035382","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919120035382/doc4.xml","form_type":"4"}},{"id":3257417,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2020-02-21T18:28:32.000Z","date":"2020-02-19","kind":"tax_withholding","acquired":false,"shares":29947,"price":3.53,"value":105712.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 25, 2017, Mr. Graham was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three year performance period ended December 31, 2019. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, the achievement of which was certified on February 19, 2020. The shares disposed represents the number of shares withheld to settle tax liability in connection with the vesting of the performance stock unit award."}],"balance_after":419548,"source":{"system":"sec-edgar","filing":"0001209191-20-011721","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919120011721/doc4.xml","form_type":"4"}},{"id":3257416,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2020-02-21T18:28:32.000Z","date":"2020-02-19","kind":"grant","acquired":true,"shares":63234,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 25, 2017, Mr. Graham was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three year performance period ended December 31, 2019. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, the achievement of which was certified on February 19, 2020. The shares disposed represents the number of shares withheld to settle tax liability in connection with the vesting of the performance stock unit award."}],"balance_after":449495,"source":{"system":"sec-edgar","filing":"0001209191-20-011721","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919120011721/doc4.xml","form_type":"4"}},{"id":3490500,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2019-06-14T17:32:57.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":170227,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest and become exercisable in three equal annual installments on the first, second and third anniversaries of the grant date."}],"balance_after":170227,"derivative":{"exercise_price":2.92,"expiration_date":"2029-06-13","underlying":"Common Stock","underlying_shares":170227},"source":{"system":"sec-edgar","filing":"0001209191-19-037213","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119037213/doc4.xml","form_type":"4"}},{"id":3490499,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2019-06-14T17:32:57.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":84760,"price":2.92,"value":247499.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant."}],"balance_after":386261,"source":{"system":"sec-edgar","filing":"0001209191-19-037213","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119037213/doc4.xml","form_type":"4"}},{"id":3494843,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2019-06-11T17:43:58.000Z","date":"2019-06-08","kind":"tax_withholding","acquired":false,"shares":11678,"price":2.81,"value":32815.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."}],"balance_after":301501,"source":{"system":"sec-edgar","filing":"0001209191-19-036147","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119036147/doc4.xml","form_type":"4"}},{"id":3494842,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2019-06-11T17:43:58.000Z","date":"2019-06-07","kind":"tax_withholding","acquired":false,"shares":12922,"price":2.81,"value":36310.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award. The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."}],"balance_after":313179,"source":{"system":"sec-edgar","filing":"0001209191-19-036147","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119036147/doc4.xml","form_type":"4"}},{"id":3503163,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2019-06-04T17:13:04.000Z","date":"2019-06-02","kind":"tax_withholding","acquired":false,"shares":15421,"price":2.79,"value":43024.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld to settle tax liability in connection with the vesting of a previously granted restricted stock unit award."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to settle tax liability in connection with the vesting of a previously granted restricted stock unit award."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents shares withheld to settle tax liability in connection with the vesting of a previously granted restricted stock unit award."}],"balance_after":326101,"source":{"system":"sec-edgar","filing":"0001209191-19-034411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119034411/doc4.xml","form_type":"4"}},{"id":3639589,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2019-02-22T18:47:33.000Z","date":"2019-02-20","kind":"tax_withholding","acquired":false,"shares":32386,"price":3.2,"value":103635.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 2, 2016, Mr. Graham was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three year performance period ended December 31, 2018. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, the achievement of which was certified on February 20, 2019. The shares disposed represents the number of shares withheld to settle tax liability in connection with the vesting of the performance stock unit award."}],"balance_after":341522,"source":{"system":"sec-edgar","filing":"0001209191-19-012777","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119012777/doc4.xml","form_type":"4"}},{"id":3639588,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2019-02-22T18:47:33.000Z","date":"2019-02-20","kind":"grant","acquired":true,"shares":84735,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 2, 2016, Mr. Graham was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three year performance period ended December 31, 2018. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, the achievement of which was certified on February 20, 2019. The shares disposed represents the number of shares withheld to settle tax liability in connection with the vesting of the performance stock unit award."}],"balance_after":373908,"source":{"system":"sec-edgar","filing":"0001209191-19-012777","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119012777/doc4.xml","form_type":"4"}},{"id":3898996,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2018-06-11T19:09:36.000Z","date":"2018-06-08","kind":"grant","acquired":true,"shares":177453,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest in equal quarterly installments over three years from the date of grant."}],"balance_after":177453,"derivative":{"exercise_price":2.7,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":177453},"source":{"system":"sec-edgar","filing":"0001209191-18-037103","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919118037103/doc4.xml","form_type":"4"}},{"id":3898995,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2018-06-11T19:09:36.000Z","date":"2018-06-08","kind":"grant","acquired":true,"shares":91667,"price":2.7,"value":247500.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents grant of restricted stock units made under the 2008 Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant."}],"balance_after":289173,"source":{"system":"sec-edgar","filing":"0001209191-18-037103","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919118037103/doc4.xml","form_type":"4"}},{"id":3898994,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2018-06-11T19:09:36.000Z","date":"2018-06-07","kind":"tax_withholding","acquired":false,"shares":12923,"price":2.7,"value":34892.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to settle tax liability in connection with the vesting of a previously granted restricted stock unit award."}],"balance_after":197506,"source":{"system":"sec-edgar","filing":"0001209191-18-037103","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919118037103/doc4.xml","form_type":"4"}},{"id":3906316,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2018-06-05T17:51:22.000Z","date":"2018-06-02","kind":"tax_withholding","acquired":false,"shares":15422,"price":2.69,"value":41485.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to settle tax liability in connection with the vesting of a previously granted restricted stock unit award."}],"balance_after":210429,"source":{"system":"sec-edgar","filing":"0001209191-18-035887","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919118035887/doc4.xml","form_type":"4"}},{"id":4287481,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP General Counsel, Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2017-06-09T16:35:06.000Z","date":"2017-06-07","kind":"grant","acquired":true,"shares":217725,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest in equal quarterly installments over three years from the date of grant."}],"balance_after":217725,"derivative":{"exercise_price":2.66,"expiration_date":"2027-06-07","underlying":"Common Stock","underlying_shares":217725},"source":{"system":"sec-edgar","filing":"0001209191-17-038903","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919117038903/doc4.xml","form_type":"4"}},{"id":4287480,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2017-06-09T16:35:06.000Z","date":"2017-06-07","kind":"grant","acquired":true,"shares":101434,"price":2.66,"value":269814.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents grant of restricted stock units made under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant."}],"balance_after":225851,"source":{"system":"sec-edgar","filing":"0001209191-17-038903","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919117038903/doc4.xml","form_type":"4"}},{"id":4287479,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":32744,"kind":"person","name":"GRAHAM PETER J","position":1,"cik":"0001235635","reported_name":"GRAHAM PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2017-06-09T16:35:06.000Z","date":"2017-06-02","kind":"tax_withholding","acquired":false,"shares":16633,"price":2.57,"value":42746.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld to settle tax liability in connection with the vesting of a restricted stock unit award that was previously granted on June 2, 2016."}],"balance_after":124417,"source":{"system":"sec-edgar","filing":"0001209191-17-038903","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919117038903/doc4.xml","form_type":"4"}}]}